

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



雲白國際有限公司
YNBY International Limited
(Incorporated in Bermuda with limited liability)
(Stock Code: 00030)

**VOLUNTARY ANNOUNCEMENT – BUSINESS UPDATE
AND
CONTINUED SUSPENSION OF TRADING**

This is a voluntary announcement made by YNBY International Limited (the “**Company**”, together with its subsidiaries, the “**Group**”). The board (the “**Board**”) of directors (the “**Directors**”) of the Company would like to provide on a voluntary basis to keep the shareholders and potential investors of the Company informed of the status of the latest business development.

THE FRAMEWORK AGREEMENT

On 24 February 2023, the Company entered into a strategy framework agreement (“**Framework Agreement**”) with JZJ Pharmaceutical Chain Group Co., Ltd.* (健之佳醫藥連鎖集團股份有限公司) (“**JZJ**”) for a term of three years, pursuant to which, the Group will (i) identify and introduce suitable pharmaceutical products, medical equipments, household chemical products, industrial products, and other quality healthcare products worldwide on behalf of JZJ; (ii) assist JZJ to source suitable original design manufacturers and/or original equipment manufacturers to produce quality products on behalf of JZJ (“**ODM/OEM Products**”) and promote the ODM/OEM Products under the Company’s sales network; and (iii) assist JZJ to source raw materials, herbs (原生藥材), plant extracts, food and biological product supplies, packaging materials, and other products worldwide. On the other hand, the JZJ will distribute the Group’s products through JZJ’s sales networks in the PRC. JZJ and the Company have also agreed to explore other opportunities, such as mergers and acquisitions and deep integration of overseas high-quality health product resources.

Information about JZJ

JZJ is a PRC company listed on the Shanghai Stock Exchange with stock code 605266. JZJ brand was founded in 1998, principally engaged in the sales of pharmaceutical products, medical equipments, healthcare products, personal care products, and etc. As of June 2023, JZJ has over 4,493 storefronts in the PRC. To the best of the Company's knowledge, information and belief after having made all reasonable enquiries, JZJ is an independent third party of the Company.

REASONS AND BENEFITS OF ENTERING INTO THE FRAMEWORK AGREEMENT

The parties' intention to enter into the Framework Agreement is based on the principle of "complementary advantages, mutual benefits, comprehensive support, and building the future together." The Directors consider that by entering into the Framework Agreement with JZJ, it will enhance the Group's influence and brand recognition in the PRC by distributing the Group's products in the PRC. The transactions contemplated under the Framework Agreement, would create new development opportunities for the Group's future business development.

The Company is also pleased to announce that the first transaction between the Group and JZJ had already been completed in October 2023, and the Group is excited to have JZJ as its business partner.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended since 9:00 a.m. on 21 June 2022 and will remain suspended. The Company will publish further announcement(s) to inform the shareholders of the Company and potential investors of any material developments in connection with the above matter as and when appropriate. The shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
YNBY International Limited
Tang Ming
Executive Director
&
Chief Executive Officer

* *For identification purpose only*

Hong Kong, 27 October 2023

As at the date of this announcement, the executive Directors are Mr. Dong Ming (Chairman), Mr. Tang Ming (Chief Executive Officer), and Mr. Liu Zhouyang; the non-executive Directors are Mr. Qian Yinghui and Mr. Huang Bin; and the independent non-executive Directors are Ms. Wong Chui San, Susan, Mr. Leung Ka Kui, Johnny and Mr. Jiang Zhi.